Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Andrew Vance who wrote (15281)	8/25/1998 2:21:00 PM
From: Hollywood	Read Replies (1) \| Respond to of 17305

Since nobody else has anything to say, here's some news for anyone still interested in NPRO: Napro BioTherapeutics Prevails in Administration Patent Suit Against Bristol-Myers Squibb BOULDER, Colo.--(BUSINESS WIRE)--Aug. 25, 1998--NaPro BioTherapeutics, Inc. (Nasdaq: NPRO - news) announced today that it has received a favorable ruling from the United Kingdom Patent Court in NaPro's patent proceeding against Bristol-Myers Squibb Company [NYSE:BMY - news]. The court ruled in favor of NaPro on NaPro's claim that a patent owned by BMS was invalid in the United Kingdom. The BMS patent in question relates to methods for administration of the anti-cancer agent paclitaxel. Sterling K. Ainsworth, Ph.D., NaPro's President and Chief Executive Officer, said that, ''We are pleased with the results in this U.K. decision. This ruling removes an important obstacle to the marketing of NaPro paclitaxel in Europe.'' NaPro BioTherapeutics, Inc., headquartered in Boulder, Colorado, is a biopharmaceutical company focused on the development, production and licensing of complex natural-product pharmaceuticals. biz.yahoo.com Hollywood